Congress Joins FDA in Focusing on Food Dye Limitations

August 27, 2025

Reading Time : 2 min

Food dye reform has been an area of focus for the Trump administration as part of its Make America Healthy Again (MAHA) initiative, giving momentum to an effort the Food and Drug Administration (FDA) had already started by banning Red No. 3 for use in food and ingested drugs. FDA has continued to prioritize this work by taking actions to phase out the use of synthetic dyes and move to natural dyes since calling for these changes earlier this year, as discussed in our previous blog on the related announcement by the administration.

In recent weeks, members of Congress have unveiled multiple pieces of legislation to reform how food dyes are regulated. Notably, on August 12, 2025, Ranking Member of the House Energy and Commerce Committee Representative Frank Pallone (D-NJ) introduced H.R. 4958, the Grocery Reform And Safety (GRAS) Act, which would make significant changes to how food additives (including food dyes) are regulated by FDA. The legislation also calls for regular safety reassessments of such substances and new resources in the form of industry user fees and by authorizing appropriations. More recently, on August 22, 2025, Representative Grace Meng (D-NY), a member of the Congressional Food Safety Caucus, introduced H.R. 5027, the Ban Harmful Food Dyes Act, a bill that would revoke the legal status of several synthetic color additives commonly used in food products. Specifically, the legislation targets dyes such as Red No. 40, Yellow No. 5, Blue No. 1 and Titanium Dioxide, proposing to deem them unsafe for use in or on food, and food containing them as adulterated under section 402(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

While it is unlikely that Congress will take up either H.R. 4958 or H.R. 5027 in the coming days or months, the introduction of these bills demonstrates that the interest in making changes to how food dyes are regulated spans multiple administrations and some members of Congress. These latest legislative developments arrive amid growing state-level activity, with numerous states having taken steps to regulate food dyes. These developments are also occurring against the backdrop of an evolving public health conversation around food additive and ultra-processed foods (UPFs) and the anticipated release of the MAHA strategy called for in the MAHA EO issued earlier this year. Taken together, these dynamics underscore that food dye reform will continue to be an evolving policy space for the foreseeable future and FDA is likely to have congressional support in continuing to prioritize regulatory reform of food ingredients. 

Share This Insight

Previous Entries

Eye on FDA

May 19, 2026

On May 12, 2026, the Food and Drug Administration (FDA) published a notice in the Federal Register requesting comment on the agency’s efforts related to drug repurposing to help address unmet medical needs. In this request for information (RFI), FDA is seeking input to identify potential new uses for FDA-approved drugs—such as a new indication or a new population—to help accelerate the availability of treatments for unmet medical needs. Stakeholders are encouraged to submit priority disease areas and potential candidates for drug repurposing, particularly in cases where there is a lack of commercial incentive to pursue labeling changes or a significant unmet need.

...

Read More

Eye on FDA

May 14, 2026

As medical chatbots proliferate, a new Pennsylvania lawsuit highlights a developing trend of states leading health artificial intelligence (AI) enforcement efforts, while the Food and Drug Administration (FDA) appears to be on the sidelines.

...

Read More

Eye on FDA

May 13, 2026

On May 12, 2026, the U.S. Food and Drug Administration (FDA) announced a major milestone in its approach to post-market oversight of chemicals in the food supply, finalizing a new proactive food chemical safety post-market assessment program and releasing two foundational papers: the “Enhanced Systematic Process for Post-Market Assessment of Chemicals in Food” and the “Tool for the Prioritization of Food Chemicals for Post-Market Assessment.”

...

Read More

Eye on FDA

May 5, 2026

In December 2016, the bipartisan 21st Century Cures Act (P.L. 114-255) was enacted, marking a pivotal milestone in advancing a patient-focused drug development (PFDD) paradigm. This law directed the Food and Drug Administration (FDA) to develop and implement strategies to solicit view of patients during the medical product development process and consider the perspectives of patients during regulatory discussions. Over the past decade, FDA has steadily taken steps to implement the 21st Century Cures Act patient-focused drug development provisions, including through meetings by which patients, caregivers, family members and patient advocates, among others, have been able to provide information about patients’ experiences with a disease or condition. The opportunity to provide such feedback through these patient-focused meetings is a key pillar of the agency’s patient-focused drug development engagement.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.